Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy
Status:
Unknown status
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal
bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the
treatment of patients with untreated symmetric proliferative diabetic retinopathy.